Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
BJU Int
    April 2024
  1. LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
    Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
    >> Share

  2. DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
    Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
    >> Share

  3. LONGONI M, Scilipoti P, Re C, Rosiello G, et al
    Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
    >> Share

  4. LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
    Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
    BJU Int. 2024;133:474-479.
    >> Share

  5. VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
    Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy.
    BJU Int. 2024;133 Suppl 4:53-63.
    >> Share

  6. BOTROS A, Rival PM, Page F, Davis ID, et al
    Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
    BJU Int. 2024;133 Suppl 4:7-10.
    >> Share

    March 2024
  7. DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
    Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
    BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
    >> Share

  8. VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
    The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
    >> Share

  9. HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
    The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
    >> Share

    February 2024
  10. HAAS M, Engelmann SU, Mayr R, Gossler C, et al
    A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
    >> Share

  11. TEMPO JA, Sii S, Ischia J, Bolton DM, et al
    Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
    BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
    >> Share

  12. CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
    Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
    BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
    >> Share


  13. Significant advances in chemotherapy for both urothelial and renal cancer.
    BJU Int. 2024;133:122-123.
    >> Share

  14. KLEMM J, Fisch M, Laukhtina E, Dahlem R, et al
    Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021.
    BJU Int. 2024;133:154-157.
    >> Share

    January 2024
  15. LU SM, Zhang Y, Dong XT, Wang JL, et al
    Microchip for detection of cell-free DNA in urine to help identify patients with bladder cancer.
    BJU Int. 2024 Jan 30. doi: 10.1111/bju.16271.
    >> Share

  16. YIM A, Alberto M, Sharma V, Green A, et al
    Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
    >> Share

    December 2023
  17. VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
    Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
    BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
    >> Share

  18. HACK J, Douglas J, Makaroff L, Costin M, et al
    Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
    >> Share

  19. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
    BJU Int. 2023;132:671-677.
    >> Share

    November 2023
  20. ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
    Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
    BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
    >> Share

    October 2023
  21. VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
    Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
    >> Share

  22. MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
    Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
    >> Share

  23. NECCHI A, Basile G, Gibb EA, Raggi D, et al
    VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
    >> Share

  24. VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
    Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
    BJU Int. 2023;132:428-434.
    >> Share

    September 2023
  25. ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
    Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
    BJU Int. 2023;132:291-297.
    >> Share

    August 2023
  26. LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
    Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
    >> Share

    July 2023
  27. CONTIERI R, Grajales V, Tan WS, Martini A, et al
    Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
    BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
    >> Share

  28. JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
    Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
    >> Share


  29. Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    >> Share

  30. DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
    Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
    BJU Int. 2023;132:84-91.
    >> Share

    June 2023
  31. BENJAMIN DJ, Lythgoe MP, Rezazadeh A
    Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    BJU Int. 2023;131:691-693.
    >> Share

  32. CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
    Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
    BJU Int. 2023;131:734-744.
    >> Share

  33. TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
    Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
    BJU Int. 2023;131:755-762.
    >> Share

  34. DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
    Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
    BJU Int. 2023;131:712-719.
    >> Share

    May 2023
  35. TAN WS, Grajales V, Bree K, Li R, et al
    BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
    BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
    >> Share

  36. RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
    Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
    BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
    >> Share

  37. LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
    Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
    BJU Int. 2023;131:571-580.
    >> Share

    April 2023
  38. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
    BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
    >> Share

  39. FREGO N, Contieri R, Diana P, Mancon S, et al
    Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk Bladder Cancer.
    BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
    >> Share

  40. ROSE KM, Narang G, Rosen G, Labatte C, et al
    Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
    BJU Int. 2023;131:471-476.
    >> Share

  41. UCHIMOTO T, Fukushima T, Komura K, Fukuokaya W, et al
    Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
    BJU Int. 2023;131:477-485.
    >> Share

    March 2023
  42. SMELSER WW, Wang J, Ogden KM, Chang SS, et al
    Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model.
    BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
    >> Share

  43. BESIROGLU H
    Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
    BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
    >> Share

  44. NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
    Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2023;131:306-312.
    >> Share

    February 2023
  45. CLAPS F, van de Kamp MW, Mayr R, Bostrom PJ, et al
    Prognostic impact of variant histologies in urothelial bladder cancer treated by radical cystectomy.
    BJU Int. 2023 Feb 6. doi: 10.1111/bju.15984.
    >> Share

  46. MIGNOT F, Fabiano E, Xylinas E, Alati A, et al
    Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients.
    BJU Int. 2023 Feb 6. doi: 10.1111/bju.15983.
    >> Share

    January 2023
  47. VON DEIMLING M, Rink M, Klemm J, Koelker M, et al
    Oncological validation and discriminative ability of pentafecta criteria after open radical cystectomy.
    BJU Int. 2023;131:90-100.
    >> Share

    December 2022
  48. ROBERSON DS, Xia L, Lee DJ, Pierorazio PM, et al
    Comparison of iROC Trial Participants to US Bladder Cancer Patients Undergoing Radical Cystectomy.
    BJU Int. 2022 Dec 22. doi: 10.1111/bju.15954.
    >> Share

  49. YANAGISAWA T, Quhal F, Kawada T, Mostafaei H, et al
    Oncologic Impact of Cystoscopic Findings in Non-Muscle Invasive Bladder Cancer: A Meta-analysis.
    BJU Int. 2022 Dec 7. doi: 10.1111/bju.15944.
    >> Share

  50. NEUZILLET Y, Leon P, Seisen T, Allory Y, et al
    A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
    BJU Int. 2022 Dec 3. doi: 10.1111/bju.15941.
    >> Share

  51. HUANG C, Assel M, Beech BB, Benfante NE, et al
    Uretero-enteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robot-assisted radical cystectomy.
    BJU Int. 2022;130:809-814.
    >> Share

  52. BRAIDE K, Kindblom J, Thellenberg Karlsson C, Stattin P, et al
    Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study.
    BJU Int. 2022;130:799-808.
    >> Share

    November 2022
  53. GHOREIFI A, Duddalwar V, Djaladat H
    Re: re: risk factors and natural history of parastomal hernia following radical cystectomy and ileal conduit.
    BJU Int. 2022;130:700-701.
    >> Share

  54. HENSLEY PJ, Bree KK, Guo CC, Lobo N, et al
    Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder.
    BJU Int. 2022;130:604-610.
    >> Share

  55. MAKRAKIS D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, et al
    Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
    BJU Int. 2022;130:592-603.
    >> Share

    September 2022
  56. YU EY, Liu YX, Chen YT, Tang QY, et al
    The Effects of Genetic Predisposition Interacted with Lifestyle Factors on Bladder Cancer Risk.
    BJU Int. 2022 Sep 2. doi: 10.1111/bju.15880.
    >> Share


  57. Updates on bladder, kidney and prostate cancers.
    BJU Int. 2022;130:275-276.
    >> Share

  58. JOHN JB, Rajaretnam N, McGrath JS, Smart NJ, et al
    Re: risk factors and natural history of parastomal hernia after radical cystectomy and ileal conduit.
    BJU Int. 2022;130:394-395.
    >> Share

  59. VENTIMIGLIA E, Villa L, Salonia A, Traxer O, et al
    Fibre optic ureteroscopes for the management of upper tract urothelial carcinoma? No thanks! Re: Flexible fibre optic vs digital ureteroscopy and enhanced vs unenhanced imaging for diagnosis and treatment of upper tract urothelial carcinoma (UTUC): re
    BJU Int. 2022;130:395-396.
    >> Share

  60. LOBO N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, et al
    Reduced-dose bacillus Calmette-Guerin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre.
    BJU Int. 2022;130:323-330.
    >> Share

  61. GHOREIFI A, Allgood E, Whang G, Douglawi A, et al
    Risk factors and natural history of parastomal hernia after radical cystectomy and ileal conduit.
    BJU Int. 2022;130:381-388.
    >> Share

    August 2022
  62. AHMADI H, Reddy S, Nguyen C, Douglawi A, et al
    Long-term renal function in patients with chronic kidney disease following radical cystectomy and orthotopic neobladder.
    BJU Int. 2022;130:200-207.
    >> Share

  63. KOBAYASHI M, Narita S, Matsui Y, Kanda S, et al
    Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
    BJU Int. 2022;130:226-234.
    >> Share

    July 2022
  64. JAMES ND, Liu W, Pirrie S, Kaur B, et al
    TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer.
    BJU Int. 2022 Jul 31. doi: 10.1111/bju.15864.
    >> Share

  65. WALRAVEN JEW, Ripping TM, Oddens JR, van Rhijn BWG, et al
    The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer.
    BJU Int. 2022 Jul 21. doi: 10.1111/bju.15856.
    >> Share

  66. DADIKHI K, Mueller F, Montani M, Thalmann GN, et al
    Case of the Month from the University Hospital of Bern, Switzerland: Urothelial carcinoma in an orthotopic neobladder: reported cases and pathophysiological hypotheses.
    BJU Int. 2022;130:38-42.
    >> Share

  67. LOIZZO D, Pandolfo SD, Del Giudice F, Cerrato C, et al
    Ureteroscopy and tailored treatment of upper tract urothelial cancer: recent advances and unmet needs.
    BJU Int. 2022;130:35-37.
    >> Share

  68. MAIBOM SL, Roder MA, Aasvang EK, Rohrsted M, et al
    Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study.
    BJU Int. 2022;130:102-113.
    >> Share

  69. AHMADI H, Ladi-Seyedian SS, Konety B, Pohar K, et al
    Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry.
    BJU Int. 2022;130:62-67.
    >> Share

  70. GRAHN A, Eisfeldt J, Malm C, Foroughi Asl H, et al
    Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
    BJU Int. 2022;130:92-101.
    >> Share

    June 2022
  71. JUBBER I, Mitchell S, Hussain S, Tsoi H, et al
    Social deprivation and bladder cancer: cause or affect for disparities in survival for affected women.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15832.
    >> Share


  72. Advances in the management of prostate and bladder cancer and recurrent urinary tract infections.
    BJU Int. 2022;129:659-660.
    >> Share

  73. CONROY S, Hubbard R, Noon AP, Hussain SA, et al
    Case of the month from the University of Sheffield, UK: Expediting definitive treatment in patients with invasive bladder cancer: an MRI-guided pathway.
    BJU Int. 2022;129:691-694.
    >> Share

  74. VEERATTERAPILLAY R, Geraghty R, Pandian R, Roy C, et al
    Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study.
    BJU Int. 2022;129:744-751.
    >> Share

  75. NURMINEN P, Ettala O, Uusitalo-Seppala R, Nummi A, et al
    Incidence of and mortality from Bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2022;129:737-743.
    >> Share

    April 2022
  76. YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
    Do we need repeat TUR after en bloc resection for pT1 bladder cancer?
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15760.
    >> Share

  77. HERZBERG H, Lifshitz K, Golan S, Baniel J, et al
    Association between early change in neutrophil-to-lymphocyte ratio after radical cystectomy and treatment outcomes.
    BJU Int. 2022 Apr 27. doi: 10.1111/bju.15757.
    >> Share

  78. ALMASSI N, Vertosick EA, Sjoberg DD, Wong NC, et al
    Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
    BJU Int. 2022;129:463-469.
    >> Share

  79. LEUNBACH TL, Stilling C, Tabor MB, Bjerggaard Jensen J, et al
    Caveats in the diagnosis of suspected non-endemic verrucous carcinoma in the urinary bladder.
    BJU Int. 2022;129:457-459.
    >> Share

  80. SUBIELA JD, Rodriguez Faba O, Aumatell J, Calderon J, et al
    Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy.
    BJU Int. 2022;129:542-550.
    >> Share

    March 2022
  81. MAISCH P, Koziarz A, Vajgrt J, Narayan V, et al
    Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
    BJU Int. 2022 Mar 2. doi: 10.1111/bju.15723.
    >> Share

  82. HASHEM A, Abdellutif MM, Laymon M, Abdullateef M, et al
    Clinical efficacy of mebeverine for persistent nocturnal enuresis after orthotopic W-neobladder.
    BJU Int. 2022;129:387-393.
    >> Share

  83. LEBRET T, Pignot G, Colombel M, Guy L, et al
    Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test.
    BJU Int. 2022;129:356-363.
    >> Share

    February 2022
  84. SCHUETTFORT VM, D'Andrea D, Quhal F, Mostafaei H, et al
    A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.
    BJU Int. 2022;129:182-193.
    >> Share

    January 2022
  85. VAN HOOGSTRATEN LMC, Witjes JA, Meijer RP, Ripping TM, et al
    Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.
    BJU Int. 2022 Jan 22. doi: 10.1111/bju.15697.
    >> Share

  86. ABOZAID M, Tan WS, Khetrapal P, Baker H, et al
    Recovery of health-related quality of life in patients undergoing robot-assisted radical cystectomy with intracorporeal diversion.
    BJU Int. 2022;129:72-79.
    >> Share

    December 2021
  87. MEISL CJ, Karakiewicz PI, Einarsson R, Koch S, et al
    Nomograms including UBC(R) Rapid Test to detect primary bladder cancer based on a multicenter data set.
    BJU Int. 2021 Dec 20. doi: 10.1111/bju.15677.
    >> Share

  88. LOBO N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, et al
    Should Patients With Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?
    BJU Int. 2021 Dec 1. doi: 10.1111/bju.15665.
    >> Share

    November 2021
  89. LEEMING RC, Karagas MR, Zens MS, Schned AR, et al
    Bladder Cancer Risk Variants and Overall and Disease-Specific Survival in Two Independent Cohorts.
    BJU Int. 2021 Nov 14. doi: 10.1111/bju.15640.
    >> Share

  90. HENSLEY PJ, Bree KK, Brooks N, Matulay J, et al
    Time interval from transurethral resection of bladder tumour to bacille Calmette-Guerin induction does not impact therapeutic response.
    BJU Int. 2021;128:634-641.
    >> Share

    October 2021
  91. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study.
    BJU Int. 2021 Oct 21. doi: 10.1111/bju.15622.
    >> Share

  92. KHADHOURI S, Gallagher KM, MacKenzie KR, Shah TT, et al
    The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study.
    BJU Int. 2021;128:440-450.
    >> Share

    September 2021
  93. GORDON NS, Baxter LA, Goel A, Arnold R, et al
    Urine dna for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: A pilot study.
    BJU Int. 2021 Sep 7. doi: 10.1111/bju.15589.
    >> Share

  94. SARI MOTLAGH R, Mori K, Laukhtina E, Aydh A, et al
    Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-anal
    BJU Int. 2021;128:280-289.
    >> Share

  95. GHODOUSSIPOUR S, Ladi Seyedian SS, Jiang D, Lifton J, et al
    Predictors of need for catheterisation and urinary retention after radical cystectomy and orthotopic neobladder in male patients.
    BJU Int. 2021;128:304-310.
    >> Share

    August 2021
  96. ELSAWY AA, Abol-Enein H, Laymon M, Ahmed AE, et al
    Predictive Value of Immunological Markers after Bacillus Calmette-Guerin Induction in Bladder Cancer.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15582.
    >> Share

  97. FURRER MA, Papa N, Luetolf S, Roth B, et al
    A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.
    BJU Int. 2021 Aug 21. doi: 10.1111/bju.15579.
    >> Share

  98. MIYATA Y, Tsurusaki T, Hayashida Y, Imasato Y, et al
    Intravesical MMC and MMC+Ara-C for non-muscle invasive bladder cancer: A randomized clinical trial.
    BJU Int. 2021 Aug 12. doi: 10.1111/bju.15571.
    >> Share

  99. ZHOU X, He P, Ji H, Wang C, et al
    Round ligament suspending treatment in orthotopic ileal-neobladder after radical cystectomy in women: a single-centre prospective randomised trial.
    BJU Int. 2021;128:187-195.
    >> Share

    July 2021
  100. LOTAN Y
    Metabolic syndrome and bladder cancer.
    BJU Int. 2021;128:1-2.
    >> Share

    June 2021
  101. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.
    >> Share

    May 2021
  102. JAHNSON S, Soderkvist P, Aljabery F, Olsson H, et al
    TERT mutation and the p53 pathway in T1 urinary bladder cancer.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15490.
    >> Share

  103. MOE A, Liow E, Redfern A, Swarbrick N, et al
    A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial
    BJU Int. 2021 May 6. doi: 10.1111/bju.15365.
    >> Share

  104. MORTEZAVI A, Crippa A, Edeling S, Pokupic S, et al
    Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group.
    BJU Int. 2021;127:585-595.
    >> Share

  105. D'ANDREA D, Matin S, Black PC, Petros FG, et al
    Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
    BJU Int. 2021;127:528-537.
    >> Share

    April 2021
  106. RAVI P, Pond GR, Diamantopoulos LN, Su C, et al
    Optimal Pathologic Response After Neoadjuvant Chemotherapy For Muscle-Invasive Bladder Cancer: Results From A Global, Multi-Center Collaboration.
    BJU Int. 2021 Apr 28. doi: 10.1111/bju.15434.
    >> Share

  107. COWAN B, Klein E, Jansz K, Westenfelder K, et al
    Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert(R) Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients.
    BJU Int. 2021 Apr 1. doi: 10.1111/bju.15418.
    >> Share

    March 2021
  108. STROTHER MC, Kutikov A, Epstein M, Bochner E, et al
    Safety of Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer and Malignant Ureteral Obstruction.
    BJU Int. 2021 Mar 29. doi: 10.1111/bju.15410.
    >> Share

  109. FICARRA V, Crestani A, Rossanese M, Alario G, et al
    Retrosigmoid ileal conduit without transposition of the left ureter after open radical cystectomy for bladder cancer.
    BJU Int. 2021 Mar 10. doi: 10.1111/bju.15375.
    >> Share

    February 2021
  110. ABRAHAMSSON J, Kollberg P, Almquist H, Blackberg M, et al
    Complete Metabolic Response with FDG-PET-CT Predicts Survival after Induction Chemotherapy in patients with Clinically Node-positive Bladder Cancer.
    BJU Int. 2021 Feb 24. doi: 10.1111/bju.15374.
    >> Share

  111. MIYAKE M, Nakai Y, Nishimura N, Ohnishi S, et al
    Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer.
    BJU Int. 2021 Feb 12. doi: 10.1111/bju.15368.
    >> Share

    January 2021
  112. BREE KK, Hensley PJ, Brooks NA, Matulay J, et al
    Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer.
    BJU Int. 2021 Jan 22. doi: 10.1111/bju.15344.
    >> Share

  113. DUNSMORE J, Duncan E, Mariappan P, de Bruin M, et al
    What influences adherence to guidance for post-operative instillation of intravesical chemotherapy to bladder cancer patients?
    BJU Int. 2021 Jan 15. doi: 10.1111/bju.15336.
    >> Share

  114. RICHTERS A, Ripping TM, Kiemeney LA, Leliveld AM, et al
    Hospital volume is associated with postoperative mortality following radical cystectomy for treatment of bladder cancer.
    BJU Int. 2021 Jan 6. doi: 10.1111/bju.15334.
    >> Share

  115. FUKUOKAYA W, Kimura T, Yanagisawa T, Kimura S, et al
    Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    BJU Int. 2021;127:90-95.
    >> Share

    December 2020
  116. STANGL FP, Thalmann GN
    Continent diversion: five decades of developments and evolution.
    BJU Int. 2020;126:653-660.
    >> Share

  117. MUILWIJK T, Akand M, Soria F, Giordano A, et al
    The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort.
    BJU Int. 2020;126:704-714.
    >> Share

    November 2020
  118. BROOKS NA, Kokorovic A, Xiao L, Matulay JT, et al
    The Obesity Paradox: Defining the impact of Body Mass Index and Diabetes Mellitus for patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin.
    BJU Int. 2020 Nov 14. doi: 10.1111/bju.15296.
    >> Share

  119. SORIA F, Black PC, Fairey AS, Cookson MS, et al
    Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
    BJU Int. 2020 Nov 5. doi: 10.1111/bju.15289.
    >> Share

  120. DEL GIUDICE F, Leonardo C, Simone G, Pecoraro M, et al
    Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the
    BJU Int. 2020;126:610-619.
    >> Share

    October 2020
  121. SPENCER-BOWDAGE S, Russell B, Rigby J, O'Kelly J, et al
    The experience of UK bladder cancer patients during the COVID-19 pandemic: A survey-based snapshot.
    BJU Int. 2020 Oct 30. doi: 10.1111/bju.15287.
    >> Share

  122. KARDOUST PARIZI M, Shariat SF, Margulis V, Mori K, et al
    Tumor infiltrating immune cells to predict response to intravesical BCG in Patients with Non-muscle invasive Bladder Cancer: A Systematic Review and meta-analysis.
    BJU Int. 2020 Oct 18. doi: 10.1111/bju.15276.
    >> Share

  123. HOSSEINI A, Mortezavi A, Sjoberg S, Laurin O, et al
    Robot-assisted intracorporeal orthotopic bladder substitution after radical cystectomy: perioperative morbidity and oncological outcomes - a single-institution experience.
    BJU Int. 2020;126:464-471.
    >> Share

    September 2020
  124. LENFANT L, Cancel-Tassin G, Gazut S, Comperat E, et al
    Genetic variability in 13q33 and 9q34 is linked to Aggressiveness Patterns and a Higher risk of progression of Non-Muscle-Invasive Bladder Cancer at the time of Diagnosis.
    BJU Int. 2020 Sep 25. doi: 10.1111/bju.15254.
    >> Share

  125. VAN DER VLIES E, Los M, Stijns PEF, van Hengel M, et al
    Preoperative frailty and outcome in patients undergoing radical cystectomy.
    BJU Int. 2020;126:388-395.
    >> Share

    August 2020
  126. HUSSEIN AA, Elsayed AS, Aldhaam NA, Jing Z, et al
    A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
    BJU Int. 2020;126:265-272.
    >> Share

    June 2020
  127. SARI MOTLAGH R, Mori K, Miura N, Quhal F, et al
    The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis.
    BJU Int. 2020 Jun 21. doi: 10.1111/bju.15146.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016